Sjogren's Syndrome malady

Categories: Rare diseases, Immune diseases

Aliases & Classifications for Sjogren's Syndrome

Aliases & Descriptions for Sjogren's Syndrome:

Name: Sjogren's Syndrome 12 25 41 42 14 69
Sicca Syndrome 12 50 25 69
Keratoconjunctivitis Sicca 25 69
Sjogren-Gougerot Syndrome 50 25
Sjogren Syndrome 12 50
Keratoconjunctivitis Sicca-Xerostomia 25
Secreto-Inhibitor-Xerodermostenosis 25
Dacryosialoadenopathia Atrophicans 25
Gougerot-Houwer-Sjogren Syndrome 25
Gougerot-Sjogren Syndrome 25
Dry Eye Syndromes 69
Sjogrens Syndrome 52
Xerodermosteosis 12
Sjögren Syndrome 25


External Ids:

Disease Ontology 12 DOID:12894
ICD10 33 M35.0 M35.00
ICD9CM 35 710.2
MeSH 42 D012859

Summaries for Sjogren's Syndrome

MedlinePlus : 41 sjogren's syndrome is an autoimmune disease. this means that your immune system attacks parts of your own body by mistake. in sjogren's syndrome, it attacks the glands that make tears and saliva. this causes a dry mouth and dry eyes. you may have dryness in other places that need moisture, such as your nose, throat, and skin. sjogren's can also affect other parts of the body, including your joints, lungs, kidneys, blood vessels, digestive organs, and nerves. most people with sjogren's syndrome are women. it usually starts after age 40. it is sometimes linked to other diseases such as rheumatoid arthritis and lupus. to make a diagnosis, doctors may use a medical history, physical exam, certain eye and mouth tests, blood tests, and biopsies. treatment focuses on relieving symptoms. it can differ for each person; it depends on what parts of the body are affected. it may include artificial tears for dye eyes and sucking on sugar-free candy or drinking water often for a dry mouth. medicines may help with severe symptoms. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary : Sjogren's Syndrome, also known as sicca syndrome, is related to marinesco-sjogren syndrome and mikulicz disease, and has symptoms including dryness of eye, eye manifestations and back pain. An important gene associated with Sjogren's Syndrome is SSB (Sjogren Syndrome Antigen B), and among its related pathways/superpathways are NF-kappaB Signaling and TNF Superfamily Pathway: Human Ligand-Receptor Interactions and their Associated Functions. The drugs Calcium carbonate and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and lung, and related phenotypes are hematopoietic system and immune system

NIH Rare Diseases : 50 sjögren syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. sjögren syndrome is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus. the hallmark symptoms of sjögren syndrome are dry mouth and dry eyes. in addition, sjogren syndrome may cause skin, nose, and vaginal dryness. it also may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain. treatment focuses on the symptoms in each person and may include moisture replacement therapies, nonsteroidal anti-inflammatory drugs and, in severe cases, corticosteroids or immunosuppressive drugs. last updated: 1/21/2016

Disease Ontology : 12 A hypersensitivity reaction type II disease that involves attack of immune cells which destroy the exocrine glands that produce tears and saliva.

Wikipedia : 71 Sjögren\'s syndrome (SjS, SS) is a long-term autoimmune disease in which the moisture-producing glands... more...

Related Diseases for Sjogren's Syndrome

Diseases in the Sjogren's Syndrome family:

Sjogren's Syndrome, Juvenile, Secondary to Autoimmune Disease

Diseases related to Sjogren's Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
id Related Disease Score Top Affiliating Genes
1 marinesco-sjogren syndrome 12.3
2 mikulicz disease 10.9
3 tenorio syndrome 10.9
4 autoimmune disease 6 10.8
5 congenital cataracts, facial dysmorphism, and neuropathy 10.8
6 systemic scleroderma 10.8
7 toxocariasis 10.2 CD79A TRIM21
8 vitamin k deficiency hemorrhagic disease 10.2 CD79A TRIM21
9 autosomal dominant charcot-marie-tooth disease type 2 due to tfg mutation 10.2 SPTAN1 TRIM21
10 corneal dystrophy, lattice type i 10.2 OPA3 SIL1
11 adamantinoma of long bones 10.2 TRIM21 TROVE2
12 respiratory system disease 10.1 APOH SSB TRIM21
13 lymph node adenoid cystic carcinoma 10.1 CD79A TRIM21 TROVE2
14 tricuspid valve disease 10.1 TRIM21 TROVE2
15 asthenopia 10.1 HSPG2 TRIM21
16 pneumoconiosis 10.1 HSPG2 TNFSF13B TRIM21
17 partial sensory epilepsy 10.1 CD79A HSPG2 TRIM21
18 46 xy gonadal dysgenesis 10.0 B2M CD79A
19 eating disorder 10.0 APOH CD79A TNFSF13B
20 membranoproliferative glomerulonephritis 10.0 APOH CD79A TRIM21
21 somatostatinoma 10.0 B2M CD79A SIL1
22 growth hormone insensitivity, partial 10.0 CHRM3 HSPG2 SPTAN1
23 chorioretinitis 10.0 APOH SSB TNFSF4 TRIM21 TROVE2
24 pseudohypoparathyroidism 10.0 APOH B2M CD79A
25 abducens nerve disease 9.9 CD79A HSPG2 TNFSF13B TRIM21
26 glycogen storage disease viii 9.9 B2M CD79A CHRM3
27 articulation disorder 9.9 APOH CD79A TNFSF13B TRIM21 TROVE2
28 congenital nystagmus 9.9 B2M CD79A
29 cataract 9.8
30 lupus erythematosus 9.7
31 amyloidosis 9.7
32 keratoconjunctivitis 9.7
33 glomerulonephritis 9.7
34 systemic lupus erythematosus 9.7
35 keratoconjunctivitis sicca 9.7
36 cousin syndrome 9.5 APOH CD79A FASLG SSB TNFSF13B TNFSF4
37 rheumatic disease 9.5
38 hepatitis c 9.5
39 epidermolysis bullosa 9.5
40 chronic active epstein-barr virus infection 9.5
41 alopecia 9.5
42 iga glomerulonephritis 9.5
43 light chain deposition disease 9.5
44 arthritis 9.5
45 tropical spastic paraparesis 9.5
46 spastic paraparesis 9.5
47 hyperglobulinemic purpura 9.5
48 spasticity 9.5
49 epidermolysis bullosa dystrophica 9.5
50 purpura 9.5

Comorbidity relations with Sjogren's Syndrome via Phenotypic Disease Network (PDN):

Acute Cystitis Deficiency Anemia
Hypothyroidism Ichthyosis Vulgaris
Osteoporosis Postinflammatory Pulmonary Fibrosis
Rheumatoid Arthritis Systemic Lupus Erythematosus

Graphical network of the top 20 diseases related to Sjogren's Syndrome:

Diseases related to Sjogren's Syndrome

Symptoms & Phenotypes for Sjogren's Syndrome

UMLS symptoms related to Sjogren's Syndrome:

dryness of eye, eye manifestations, back pain, muscle cramp, sciatica

MGI Mouse Phenotypes related to Sjogren's Syndrome:

id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 TNFSF13B TNFSF4 TRIM21 TROVE2 B2M CD79A
2 immune system MP:0005387 9.65 B2M CD79A CXCL13 FASLG HSPG2 SSB
3 liver/biliary system MP:0005370 9.1 B2M CD79A CHRM3 FASLG HSPG2 OPA3

Drugs & Therapeutics for Sjogren's Syndrome

Drugs for Sjogren's Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Calcium carbonate Approved Phase 4 471-34-1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3 50-18-0, 6055-19-2 2907
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
Pilocarpine Approved Phase 4 54-71-7, 92-13-7 5910
Glycerol Approved, Experimental Phase 4 56-81-5 753
Dehydroepiandrosterone Approved, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
13 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
14 Antacids Phase 4,Phase 2
15 Antifungal Agents Phase 4,Phase 2
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Anti-Inflammatory Agents Phase 4,Phase 2
18 Antineoplastic Agents, Hormonal Phase 4,Phase 2
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Anti-Ulcer Agents Phase 4,Phase 2
21 Calcineurin Inhibitors Phase 4,Phase 2
22 Calcium, Dietary Phase 4
23 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Gallopamil Phase 4
25 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
26 glucocorticoids Phase 4,Phase 2
27 Hormone Antagonists Phase 4,Phase 2
28 Hormones Phase 4,Phase 2
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Vaccines Phase 4
32 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Nasal Decongestants Phase 4,Phase 3,Phase 2,Phase 1
35 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1
36 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
37 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1
39 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antiemetics Phase 4,Phase 2
41 BB 1101 Phase 4,Phase 2
42 Dexamethasone 21-phosphate Phase 4,Phase 2
43 Dexamethasone acetate Phase 4,Phase 2 1177-87-3
44 HIV Protease Inhibitors Phase 4,Phase 2
protease inhibitors Phase 4,Phase 2
46 Cholinergic Agents Phase 4
47 Neurotransmitter Agents Phase 4,Phase 1,Phase 2
48 Carbopol 940 Phase 4
49 Castor Oil Phase 4
50 Cathartics Phase 4

Interventional clinical trials:

(show top 50) (show all 158)
id Name Status NCT ID Phase
1 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4
2 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention Completed NCT00631358 Phase 4
5 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4
6 A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment Completed NCT00438048 Phase 4
7 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4
8 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
9 Effect of Pilocarpine in Patients With Xerostomia Recruiting NCT02982577 Phase 4
10 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
11 Efficacy of Tocilizumab in Primary Sjögren's Syndrome. Unknown status NCT01782235 Phase 2, Phase 3
12 Treatment of Salivary Gland Hypofunction With Neuro- Electrostimulation Unknown status NCT01174329 Phase 2, Phase 3
13 Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye Unknown status NCT02257957 Phase 3
14 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3
15 Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome Completed NCT00632866 Phase 3
16 Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome Completed NCT01601028 Phase 3
17 A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503189 Phase 3
18 Tolerance and Efficacy of Rituximab in Sjogren's Disease Completed NCT00740948 Phase 2, Phase 3
19 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3
20 Preventive IVIG Therapy for Congenital Heart Block Completed NCT00460928 Phase 2, Phase 3
21 Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome Recruiting NCT02067910 Phase 3
22 A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome Recruiting NCT02915159 Phase 3
23 Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome Recruiting NCT02066896 Phase 3
24 A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Recruiting NCT02503163 Phase 3
25 An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Recruiting NCT02503176 Phase 3
26 Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood Enrolling by invitation NCT02153515 Phase 3
27 Effect of Saliva Substitutes on Dental Hard Tissues in Situ Terminated NCT01165970 Phase 2, Phase 3
28 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3
29 Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS) Unknown status NCT00953485 Phase 1, Phase 2
30 A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome Unknown status NCT02464319 Phase 2
31 Low Dose Cyclosporin A in Primary Sjögren Syndrome Completed NCT01693393 Phase 2
32 A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome Completed NCT00852839 Phase 2
33 Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome Completed NCT01008982 Phase 2
34 Etanercept Therapy for Sjogren's Syndrome Completed NCT00001954 Phase 2
35 Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome Completed NCT01160666 Phase 2
36 Pilot Study of Thalidomide to Treat Sjogren's Syndrome Completed NCT00001599 Phase 2
37 Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome Completed NCT00391924 Phase 2
38 Exploratory Study for Dry Mouth in Patients With Sjögren’s Syndrome Completed NCT00233363 Phase 2
39 Rituximab Treatment in Sjogren's Syndrome Completed NCT00363350 Phase 1, Phase 2
40 Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome Completed NCT00637793 Phase 2
41 DHEA Treatment for Sjogren's Syndrome Completed NCT00001598 Phase 2
42 Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome Completed NCT00426543 Phase 2
43 Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome Completed NCT00683345 Phase 2
44 An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness Completed NCT01369589 Phase 1, Phase 2
45 Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops Completed NCT00001731 Phase 2
46 Green Tea Lozenges for the Management of Dry Mouth Completed NCT01647737 Phase 1, Phase 2
47 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye Completed NCT01393132 Phase 2
48 A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS) Completed NCT02402309 Phase 2
49 Dexamethasone Irrigation of the Parotid Glands in Primary Sj(SqrRoot)(Delta)Gren s Syndrome Subjects Completed NCT01316770 Phase 2
50 Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome Recruiting NCT02291029 Phase 2

Search NIH Clinical Center for Sjogren's Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :

Cochrane evidence based reviews: sjogren's syndrome

Genetic Tests for Sjogren's Syndrome

Anatomical Context for Sjogren's Syndrome

MalaCards organs/tissues related to Sjogren's Syndrome:

Eye, Skin, Lung, Testes, Kidney, Thyroid, Salivary Gland

Publications for Sjogren's Syndrome

Articles related to Sjogren's Syndrome:

(show top 50) (show all 267)
id Title Authors Year
A Potential of sFasL in Preventing Gland Injury in Sjogren's Syndrome. ( 28326325 )
Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome. ( 28074193 )
Paeoniflorin ameliorates symptoms of experimental Sjogren's syndrome associated with down-regulating Cyr61 expression. ( 26630293 )
Hypokalemic Paralysis in Sjogren's Syndrome Secondary to Renal Tubular Acidosis. ( 27731561 )
Mixed Connective Tissue Disorder Complicated by Polymyositis, Sjogren's Syndrome, Pleural Effusion and Pericarditis. ( 28083450 )
TAFRO syndrome with primary Sjogren's syndrome. ( 27795506 )
Autonomic dysfunction in primary Sjogren's syndrome: a prospective cohort analysis of 154 Korean patients. ( 27017389 )
Central pontine myelinolysis in Sjogren's syndrome with hypokalemia. ( 26929036 )
Sjogren's syndrome presenting as Hypokalemic paralysis due to distal renal tubular acidosis. ( 27728182 )
IL-22 receptor 1 is over-expressed in primary Sjogren's Syndrome and Sjogren-associated non-Hodgkin lymphomas and is regulated by IL-18. ( 25880879 )
NOD.H-2h4 mice: an important and underutilized animal model of autoimmune thyroiditis and Sjogren's syndrome. ( 25727287 )
Hypokalemic paralysis as a primary presentation of Fanconi's syndrome and distal renal tubular acidosis in a patient with primary Sjogren's syndrome. ( 26053828 )
Entropy of corneal nerve fibers distribution observed by laser scanning confocal microscopy: A noninvasive quantitative method to characterize the corneal innervation in Sjogren's syndrome patients. ( 26499877 )
Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations. ( 25886059 )
Microscopic polyangiitis associated with primary biliary cirrhosis, Sjogren's syndrome and Hashimoto's thyroiditis. ( 25758890 )
The Clinical Characteristics of Primary Sjogren's Syndrome With Neuromyelitis Optica Spectrum Disorder in China: A STROBE-Compliant Article. ( 26181553 )
Effect of Chinese herbal medicines for nourishing yin, supplementing qi, and activating blood on reproductive endocrine activity and immune functions in patients with primary Sjogren's syndrome. ( 26525549 )
Investigation of novel autoantibodies in Sjogren's syndrome utilizing Sera from the Sjogren's international collaborative clinical alliance cohort. ( 25881294 )
Contribution of dendritic cell immunoreceptor (DCIR) polymorphisms in susceptibility of systemic lupus erythematosus and primary Sjogren's syndrome. ( 26429306 )
IL-36I+ axis is modulated in patients with primary Sjogren's Syndrome. ( 25902739 )
Renal tubular acidosis due to Sjogren's syndrome presenting as hypokalemic quadriparesis: A report of two cases. ( 26664220 )
Serotonin transporter gene polymorphisms: Relation with platelet serotonin level in patients with primary Sjogren's syndrome. ( 25903736 )
Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome. ( 23736535 )
Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjogren's syndrome. ( 24433480 )
Chemokine receptor 5 I932 polymorphism and systemic lupus erythematosus, vasculitis, and primary Sjogren's syndrome. Meta-analysis of possible associations. ( 24599359 )
A Rare Case of Neuromyelitis Optica Spectrum Disorder in Patient with Sjogren's Syndrome. ( 25506022 )
Porphyria cutanea tarda and Sjogren's syndrome. ( 25054769 )
Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. ( 23968620 )
Atypical presentation of systemic lupus erythematosus: parotitis and secondary Sjogren's syndrome. Case report. ( 25076705 )
Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome. ( 24153350 )
CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren's syndrome. ( 24966908 )
Pyoderma gangrenosum: intractable leg ulcers in Sjogren's syndrome. ( 25224774 )
Osteomalacia complicating renal tubular acidosis in association with Sjogren's syndrome. ( 25193912 )
Classification criteria for Sjogren's syndrome: nothing ever stands still! ( 24092418 )
Meta-analysis of differentially expressed genes in primary Sjogren's syndrome by using microarray. ( 24090683 )
EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. ( 23940214 )
Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. ( 25081016 )
Association between Sjogren's Syndrome and Respiratory Failure: Put Airway, Interstitia, and Vessels Close Together: A National Cohort Study. ( 25350278 )
Xerophthalmia of Sjogren's Syndrome Diagnosed with Anti-Salivary Gland Protein 1 Antibodies. ( 25076899 )
The impact of primary Sjogren's syndrome on pregnancy outcome: our series and review of the literature. ( 24044939 )
Cancer Diagnosis in a Cohort of Patients with Sjogren's Syndrome and Rheumatoid Arthritis: A Single-center Experience and Review of the Literature. ( 25368273 )
Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). ( 24162151 )
Sjogren's syndrome and acquired splenic atrophy with septic shock: a case report. ( 24393211 )
Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases. ( 24326481 )
Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome. ( 24385203 )
Hypokalemic rhabdomyolysis: an unusual presentation of Sjogren's syndrome. ( 24165505 )
Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome. ( 23910012 )
Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial. ( 22851468 )
IL-34 is overexpressed in the inflamed salivary glands of patients with Sjogren's syndrome and is associated with the local expansion of pro-inflammatory CD14(bright)CD16+ monocytes. ( 23392590 )
Activity of T-helper cells in patients with primary Sjogren's syndrome. ( 23422488 )

Variations for Sjogren's Syndrome

Expression for Sjogren's Syndrome

Search GEO for disease gene expression data for Sjogren's Syndrome.

Pathways for Sjogren's Syndrome

Pathways related to Sjogren's Syndrome according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
Show member pathways

GO Terms for Sjogren's Syndrome

Cellular components related to Sjogren's Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 APOH B2M CXCL13 FASLG HSPG2 SIL1

Biological processes related to Sjogren's Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.35 B2M CXCL13 FASLG TNFSF13B TNFSF4
2 tumor necrosis factor-mediated signaling pathway GO:0033209 9.33 FASLG TNFSF13B TNFSF4
3 positive regulation of T cell cytokine production GO:0002726 8.62 B2M TNFSF4

Molecular functions related to Sjogren's Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CXCL13 FASLG TNFSF13B TNFSF4
2 tumor necrosis factor receptor binding GO:0005164 8.8 FASLG TNFSF13B TNFSF4

Sources for Sjogren's Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....